Valuation of the CT LI-RADS treatment response V2018 in patients after first-line DEB-TACE for hepatocellular carcinoma (HCC)

Gợi ý tài liệu liên quan:

• Accurate prediction of HCC risk after SVR in patients with hepatitis C cirrhosis based on longitudinal data

  11 trang 25 0 0

• MYBL2 regulates de novo purine synthesis by transcriptionally activating IMPDH1 in hepatocellular carcinoma cells

  13 trang 23 0 0

• Analysis of the expression and prognostic significance of DDK complex in Hepatocarcinoma

  12 trang 23 0 0

• Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma

  17 trang 20 0 0

• Circulating tumor cells in hepatocellular carcinoma: A pilot study of detection, enumeration, and next-generation sequencing in cases and controls

  11 trang 19 0 0

• Efficacy and safety analysis of TACE+Donafenib+Toripalimab versus TACE+Sorafenib in the treatment of unresectable hepatocellular carcinoma: A retrospective study

  11 trang 19 0 0

• Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors

  16 trang 18 0 0

• Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: A systematic review and meta-analysis of randomized controlled trials

  11 trang 17 0 0

• Liver-specific lncRNA FAM99A may be a tumor suppressor and promising prognostic biomarker in hepatocellular carcinoma

  19 trang 16 0 0

• Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint

  11 trang 16 0 0